Close
Planning and Development Division
Challenge to new field
“Challenging Sprit”
- HOME >
- Businesses and Products >
- Planning and Development Division >
- Healthcare Business Development Department >
- Oligonucleotide Drug Discovery Platform
Oligonucleotide Drug Discovery Platform
Nissan Chemical’s oligonucleotide drug discovery platform, including (1) modified nucleic acid MCEs, (2) single-stranded herteroduplex oligonucleotides, and (3) in silico sequence design algorithms, provides antisense oligonucleotide therapeutics with high efficacy and safety.
MCE is a novel 2'-O-modified ribonucleoside discovered by Tokyo Institute of Technology. MCE-modified oligonucleotide is known for its high resistance to nucleases and less hepatotoxicity. We are exploring MCE-modified oligonucleotide therapeutics under licence from Tokyo Institute of Technology.
Single-stranded herteroduplex oligonucleotide (ss-HDO) is a novel antisense oligonucleotide with the unique structure. ss-HDO consists of a gapmer, which has modified ribonucleotides at both ends of the sequence, and a complementary RNA strand, and they are connected by a linker. ss-HDO shows high in vivo activity against its parent ASO and is also easy to be attached to targeting ligands to achieve the desired drug delivery profile.
We are working on innovative oligonucleotide drug discovery using our own platform through in-house research and collaborations with pharmaceutical companies to build our R&D portfolio.
Contact Us
Handling division
- Healthcare Business Development Department
